Aim: In this multicenter study, we aimed to compare hepatic and tumor related outcomes of local regional therapy for HCC in patients with chronic HBV or HCV with and without the MetS. Method: Patients with viral hepatitis treated with local regional therapy (transarterial chemoembolization +/− radiofrequency ablation) for HCC between 2007–2013 in two large Sydney hospitals were included in this retrospective study. Medical records for these patients were audited for patient demographics, hepatic and tumor characteristics at diagnosis, number and intervals of local regional therapy as well as episodes of hepatic decompensation (jaundice, ascites, varices, encephalopathy, infections). Patients with viral hepatitis were classified

into 2 groups according to the presence of absence of the MetS, as defined by the Adult Treatment Panel III. Results: A total of 69 patients were included in the study, 32 patients with the MetS GSK126 in vitro and 37 patients without. The mean age of the whole group was 60.9 ± 12.1 and the male to CSF-1R inhibitor female ratio was 4.31. Demographics and clinical data of patients with and without the

MetS are presented in table 1. With respect to tumor response outcomes, there was no statistical difference in the average number of local regional therapy sessions in both groups (2.3 ± 1.62 vs 2.1 ± 1.53, p = 0.5373), and the intervals between therapies. In contrast, with respect to hepatic decompensations; significantly more episodes of hepatic decompensation were seen in those with MetS than those without MetS (34% vs 11%, p = 0.0220). Table 1: Patient demographics and clinical data.   With this website MetS Without MetS p-value Number 32 37 – Age 63.2 ± 10.39 59 ± 13.02 – Male (%) 27 (84%) 29 (78%) 0.5562 %HBV 9 (28%) 23 (62%) 0.0075 %HCV 23 (72%) 14 (38%) 0.0075 Mean Child-Pugh score 6.25 ± 1.83 6.19 ± 1.26 0.8836 Mean max size of lesion (cm) 4.18 ± 2.85 3.84 ± 2.35 0.588 Conclusion: In patients with HCC and viral hepatitis treated with local regional therapy, presence of metabolic syndrome is associated with significantly

higher rates of hepatic decompensation. GS BURNS,1 JA HOLMES,1 R GOLDBERG,1 R TRETHOWAN,1 A WONG,1 O CRONIN,1 NA KURUVILLA,1 T NGUYEN,1 RG SHAW,1 RY CHEN,1 BH DEMEDIUK,1 SJ BELL,1 SA LOCARNINI,2 DS BOWDEN,2 PV DESMOND,1 AJ THOMPSON1 1St Vincent’s Hospital, Melbourne, Australia, 2Victorian Infectious Diseases Laboratory, Melbourne, Australia Introduction: The immune control (IC) phase of chronic hepatitis B (CHB) is defined by HBV DNA < 2000 IU/mL and normal ALT. It has recently been suggested that a single-point HBsAg level <1000 IU/mL is an accurate biomarker for identifying IC patients with a low risk of HBV reactivation at 12 months.(1) The aim of this project was to validate this rule in a cohort of patients with long-term follow-up. Methods: A database search was used to identify treatment naïve patients in the IC phase of CHB for whom an HBsAg level was available, with a minimum of 12 months of follow-up.